Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We present a critical overview of past clinical trials, how therapies are selected for testing in people, challenges with ALS clinical trial design and conduct, and ways to best move forward. © 2008.
Aggarwal, S., & Cudkowicz, M. (2008). ALS Drug Development: Reflections from the Past and a Way Forward. Neurotherapeutics, 5(4), 516–527. https://doi.org/10.1016/j.nurt.2008.08.002